By Alex Langton | 23 October 2023
Mike Caine and I have a financial interest in OptiBiotix Health.
In a strategic move aimed at revolutionising India's health and wellness landscape, OptiBiotix Health, a pioneering life sciences company focused on combatting obesity, high cholesterol, diabetes, and skincare issues, has announced a groundbreaking agreement with Tata Chemicals Limited. This collaboration is set to transform the Indian market by infusing Tata's proprietary Fossence® into OptiBiotix's renowned products, SlimBiome® and LeanBiome®.
The heart of this agreement lies in the integration of Tata's Fossence®, a proprietary short-chain fructo-oligosaccharide (FOS), into OptiBiotix's SlimBiome® and LeanBiome® offerings specifically designed for the Indian market.
Fossence® will replace the existing FOS component used in SlimBiome® in other markets, thereby introducing an element of scientific substantiation regarding the health benefits associated with FOS within the Indian consumer space.
Tata Chemicals, a global science powerhouse with a diverse presence in industrial chemicals, food and nutrition under Tata NQ, and agriculture, is a publicly listed entity on the Indian stock exchange. As part of the illustrious Tata Group, which boasts an impressive workforce of over one million individuals and reported annual revenues of $300 billion in 2022, Tata Chemicals' stature in the global business arena is undeniable.
The significance of this collaboration transcends the mere amalgamation of two distinct entities; it epitomises the convergence of pioneering scientific innovation and trusted legacy. OptiBiotix's commitment to addressing pressing health concerns such as obesity, high cholesterol, diabetes, and skincare aligns seamlessly with Tata Chemicals' mission to explore the realms of science for the betterment of society by incorporating Tata's Fossence® into its products. OptiBiotix enhances its efficacy and leverages the rich heritage and scientific expertise that Tata Chemicals embodies.